You are using an older browser version. Please use a supported version for the best MSN experience.

Coronavirus vaccine: Singapore scientists discover 5 antibodies that can combat COVID

Business Today logoBusiness Today 17/6/2020 BusinessToday.In
a close up of a bottle: Coronavirus vaccine: Singapore scientists discover 5 antibodies that can combat COVID © India Today Group Coronavirus vaccine: Singapore scientists discover 5 antibodies that can combat COVID

A team of scientists in Singapore has discovered five antibodies that can block coronavirus and protect against the key mutations developed in the virus, according to the country's defence research and development organisation, Defence Science Organisation (DSO). PTI reported that the human trials for the lead antibody, AOD01 will begin in the upcoming months after getting approved from the Health Sciences Authority.

Scientists at the DSO have screened "hundreds of thousands" of B cells from the blood samples of the novel coronavirus patients who have recovered since March this year. B cells are the cells that produce antibodies to target pathogens. Within a month of receiving these blood samples from the National Centre for Infectious Diseases and Singapore General Hospital, the scientists managed to isolate the first two antibodies for testing.

Another three effective antibodies were, however, identified three months later through a technique wherein B cells are screened simultaneously with the live virus, allowing antibodies with effective virus neutralising properties to be identified. According to a Channel News Asia report, this technique was developed jointly by the DSO, National University of Singapore's Yong Loo Lin School of Medicine and Life Sciences Institute over the past 5 years.

Results prove that these five antibodies "demonstrate neutralisation" against coronavirus, the DSO said. It further added that these antibodies are "all potent in blocking infection and effective against key mutations that have emerged in the virus during the pandemic."

According to Dr Conrad Chan, a senior scientist at DSO, the research phase is now completed and the study is now transitioning into the pre-clinical phase, where the team is preparing this antibody for production. Dr Chan further said that this will allow clinical trials to be conducted and manufacturing will be ramped up if human trials are successful.

📰 MORE ON MICROSOFT NEWS

Also on MSN:

Are we close to a cure for COVID-19?

(content provided by Showbizz Daily)

More From Business Today

image beaconimage beaconimage beacon